Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Rises By 20.8%

Pulmatrix, Inc. (NASDAQ:PULM) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 47,700 shares, a growth of 20.8% from the December 31st total of 39,500 shares. Based on an average daily trading volume, of 463,900 shares, the short-interest ratio is presently 0.1 days. Currently, 1.3% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Pulmatrix in a research report on Sunday, January 5th. They set a “hold” rating on the stock.

Pulmatrix Stock Performance

NASDAQ PULM traded down $0.20 during trading hours on Monday, hitting $7.50. The company had a trading volume of 38,164 shares, compared to its average volume of 39,441. The firm has a 50 day simple moving average of $6.40 and a 200 day simple moving average of $3.81. Pulmatrix has a 52 week low of $1.55 and a 52 week high of $8.44. The firm has a market capitalization of $27.38 million, a price-to-earnings ratio of -2.84 and a beta of 1.61.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings data on Friday, November 8th. The biotechnology company reported ($0.71) EPS for the quarter. The firm had revenue of $0.37 million during the quarter. Pulmatrix had a negative net margin of 96.51% and a negative return on equity of 45.97%.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.